Plus Therapeutics, Inc. announced that Gregg Lapointe submitted his resignation as a member of the Board of Directors, effective immediately. Mr. Lapointe's decision to resign did not result from any disagreement with the company on any matter relating to the company's operations, policies or practices. On February 6, 2020, the Board of Directors of the company appointed Mr. Greg Petersen to the Board, effective as of February 14, 2020.

Mr. Petersen was appointed to the Board upon the recommendation of the Governance and Nominating Committee of the Board and pursuant to the bylaws of the Company. Mr. Petersen is expected to serve on the Compensation Committee and Audit Committee of the Board. Mr. Petersen is an accomplished Executive and Board member with more than 25 years of strategy, operations, finance and compliance leadership experience.

His 10 years of Board of Directors experience includes his current roles as Compensation Committee Chair and Audit Committee member of PROS Holdings and as Audit Committee Chair of Mohawk Group Holdings. Mr. Petersen has served as Executive Vice Chairman of Diligent Corporation and as Chief Financial Officer of Lombardi Software and Activant Solutions (now part of Epicor). He has also held executive positions at American Airlines and other corporations.

On February 6, 2020, the Company announced the appointment of Andrew Sims as Vice President of Finance and Chief Financial Officer of the Company. Mr. Sims will be the Company's principal financial officer and principal accounting officer effective upon the commencement of his employment with the Company. Prior to joining the Company, Mr. Sims was Partner at Mazars, a global accounting, advisory, audit, tax and consulting firm.

Working from both the Oxford, England and New York offices, Mr. Sims audited and advised global public clients, including a variety of healthcare companies. Further, he was the lead partner on over 50 acquisitions.